With the increasing use of GLP-1/GIP agonists for both diabetes and obesity, it is imperative for clinicians to include these agents in the differential diagnosis when evaluating new-onset GI symptoms, particularly in patients without a history of abdominal surgery. This evidence concerns the gene GIP and Obesity.